Compare Bristol-Myers Squibb Co (BMY) vs Costco Wholesale Corporation (COST) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Bristol-Myers Squibb Co vs Costco Wholesale Corporation — how do they compare? Bristol-Myers Squibb Co trades at $63.84 (market cap $129.94B), while Costco Wholesale Corporation trades at $948.82 (market cap $418.79B). The key difference: Costco Wholesale Corporation is far larger — about 3.2× Bristol-Myers Squibb Co's market cap, and Bristol-Myers Squibb Co pays the higher dividend (3.96%). Which is the better fit depends on your goals.
| BMY | COST | |
|---|---|---|
Market Cap | $129.94B | $418.79B |
Sector | Health | Consumer Staples |
52-Week High | $65.89 | $1.09K |
52-Week Low | $42.60 | $849.63 |
Enterprise Value | $163.92B | $406.93B |
Dividend Yield | 3.96% | 0.62% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Bristol Myers Squibb (BMY) trades at $63.83, down 1.56% today, with strong technical bullish signals and consistent earnings beats. The stock shows robust fundamentals with a 14.01 P/E ratio, 18.87% net margin, and recent $2.3 billion manufacturing investment. Analyst consensus leans neutral with a $68.56 price target, while technical indicators suggest bullish momentum with key support at $63.
BMY presents a balanced opportunity with strong profitability and growth pipeline offset by patent expiration risks. The stock's current valuation appears reasonable with upside potential to analyst targets, though investors should monitor debt levels and competitive pressures in the pharmaceutical sector.
Costco Wholesale Corporation (COST) trades at $948.1, down 0.49% on the day, with a bearish technical signal from moving averages but neutral oscillators. The company reported strong revenue growth to $275.24B in 2025 and net income of $8.10B, though it missed Q1 2026 EPS estimates. Recent news highlights March sales up 11.3% year-over-year and institutional buying activity, while the stock remains near its 52-week high of $1,067.08.
Outlook is supported by robust membership fee growth and expansion, but high valuation ratios like a P/E of 47.5 pose risks. Analyst consensus is bullish with a $1,120 price target, though competitive pressures and economic sensitivity could challenge margins. The stock offers long-term growth potential if valuation aligns with earnings momentum.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Bristol-Myers Squibb Co
Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Unlike some of its more diversified peers, Bristol has exited several nonpharmaceutical businesses to focus on branded specialty drugs, which tend to support strong pricing power.
Read more on BMY →About Costco Wholesale Corporation
The leading warehouse club, Costco has 815 stores worldwide (at the end of fiscal 2021), with most sales derived in the United States (72%) and Canada (14%). It sells memberships that allow customers to shop in its warehouses, which feature low prices on a limited product assortment. Costco mainly caters to individual shoppers, but roughly 20% of paid members carry business memberships. Food and sundries accounted for 40% of fiscal 2021 sales, with non-food merchandise 29%, warehouse ancillary and other businesses (such as fuel and pharmacy) nearly 17%, and fresh food 14%. Costco's warehouses average around 146,000 square feet
Read more on COST →
